Showing 1 to 1 of 1 results
forbes.com
🌐 75% Global Worthiness


Sarepta Stock Surges After FDA Lifts Hold on Elevidys
Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.
Sarepta Stock Surges After FDA Lifts Hold on Elevidys
Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.
Progress
44% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results